Evidence map›Paper›PMID 34064314›Full record

ArticleJournal of clinical medicine2021

Risk of SARS-CoV-2 Infection in Previously Infected and Non-Infected Cohorts of Health Workers at High Risk of Exposure.

Adrián Sánchez-Montalvá, Candela Fernández-Naval, Andrés Antón, Xavier Durà, Alba Vimes, Aroa Silgado, Fernando Velásquez-Orozco, Juan Espinosa-Pereiro, Fernando Salvador, Tomás Pumarola and 2 more

Open access · goldAbstract read
In one paragraph

Article in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Adrián Sánchez-MontalváInfectious Diseases Department, Vall d'Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Candela Fernández-NavalMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-5584-3537
Andrés AntónMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Xavier DuràInfectious Diseases Department, Vall d'Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Alba VimesClinical Pharmacology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08193 Barcelona, Spain.
Aroa SilgadoMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Fernando Velásquez-OrozcoMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Juan Espinosa-PereiroInfectious Diseases Department, Vall d'Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-7238-8337
Fernando SalvadorInfectious Diseases Department, Vall d'Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-0546-1354
Tomás PumarolaMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.
Benito AlmiranteInfectious Diseases Department, Vall d'Hebron University Hospital, International Health Program of the Catalan Insitute of Health (PROSICS), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0002-1189-2361
Juliana EsperalbaMicrobiology Department, Vall d'Hebron University Hospital, Vall d'Hebron Barcelona Hospital Campus, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain.ORCID 0000-0003-1326-1341
Universitat Autònoma de Barcelona · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The objective of this study is to assess the risk of newly acquired RNA detection-proven SARS-CoV-2 infection after previous SARS-CoV-2 infection. This is a prospective study conducted from March to September 2020 in Barcelona, Spain. Healthcare workers caring for SARS-CoV-2 infected patients were divided in two cohorts: (a) previously RNA-proven SARS-CoV-2 infected cohort with mild symptoms (IC) and (b) healthy cohort (HC). Weekly SARS-CoV-2 RNA detection assays from nasopharyngeal swabs were performed. Serology status was assessed at the beginning and at the end of the study. Twenty participants were included in each group. The median age was 30 (IQR 27-34.75) years, and 55% were female. The median time of follow up was 49 (IQR 49-51) days. Fifteen out of 246 (6%) nasopharyngeal swab samples were positive for SARS-CoV-2, all in the IC. The percentage of participants in the IC with a probable newly acquired SARS-CoV-2 RNA-proven infection was 20% (95% IC 5.7-43.6%) at the end of the 7-week follow up period. The incidence reinfection rate was 28.6 (95% IC 7.8-73.2) cases per 1000 person-week. Despite detectable IgG antibodies against SARS-CoV-2 participants highly exposed to SARS-CoV-2 may develop a newly acquired SARS-CoV-2 RNA detection episode during the first months after the initial infection.

Indexed as

genome amplification diagnostic assaysnatural immunityreinfectionSARS-CoV-2serology

Identifiers

PMID34064314
PMCPMC8124281
OpenAlexW3157253626

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.